tiprankstipranks
Trending News
More News >
Calidi Biotherapeutics (CLDI)
:CLDI
US Market

Calidi Biotherapeutics (CLDI) Income Statement

Compare
359 Followers

Calidi Biotherapeutics Income Statement

Last quarter (Q3 2025), Calidi Biotherapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Calidi Biotherapeutics's net income was $-5.15M. See Calidi Biotherapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 0.00$ 0.00$ 45.00K$ 449.00K$ 0.00
Gross Profit
$ 0.00$ -1.26M$ -229.00K$ 355.00K$ 0.00
Operating Expenses
$ 21.78M$ 27.74M$ 22.90M$ 10.84M$ 6.77M
Depreciation and Amortization
$ 1.53M$ 1.26M$ 260.00K$ 156.00K$ 107.00K
EBITDA
$ -19.73M$ -24.20M$ -25.00M$ -9.45M$ -6.67M
Operating Income
$ -21.78M$ -28.99M$ -23.13M$ -10.48M$ -6.77M
Other Income/Expenses
$ -419.00K$ -208.00K$ -2.29M$ 13.88M$ -1.16M
Pretax Income
$ -22.20M$ -29.20M$ -25.42M$ 3.40M$ -7.93M
Net Income
$ -22.14M$ -29.22M$ -25.43M$ -10.93M$ -7.94M
Per Share Metrics
Basic EPS
$ -35.70$ -207.61$ -358.80$ 14.16$ -2.64
Diluted EPS
$ -35.70$ -207.61$ -358.80$ 14.16$ -2.64
Weighted Average Shares Outstanding
664.41K 140.16K 70.59K 238.63K 2.98M
Weighted Average Shares Outstanding (Diluted)
664.41K 140.16K 70.59K 238.63K 2.98M
Currency in USD

Calidi Biotherapeutics Earnings and Revenue History